You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Induction Therapy for the Older/Unfit Patient

  • Authors: Daniel A. Pollyea, MD, MS
  • CME / ABIM MOC Released: 11/23/2019
  • Valid for credit through: 11/23/2020
Start Activity

Target Audience and Goal Statement

This activity is intended for hematology/oncology specialists.

The goal of this activity is to provide clinicians with expert insight on optimal approaches to induction therapy in older or unfit patients who are not candidates for intensive induction chemotherapy.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Recommendations for induction therapy in patients with acute myeloid leukemia (AML) who are not eligible for intensive induction chemotherapy
    • Emerging agents being evaluated for use in patients with AML who are not candidates for intensive induction chemotherapy


As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


  • Daniel A. Pollyea, MD, MS

    Associate Professor of Medicine
    Clinical Director of Leukemia Services
    Robert H. Allen MD Chair in Hematology Research
    Division of Hematology
    University of Colorado School of Medicine
    Denver, Colorado


    Disclosure: Daniel A. Pollyea, MD, MS, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie Inc.; Agios Pharmaceuticals; Celgene Corporation; Daiichi SankyoInc.; Gilead Sciences, Inc.; PfizerInc.
    Received grants for clinical research from: AbbVie Inc.; Pfizer Inc.
    Other: DSMC -GlycoMimetrics


  • Melinda Tanzola, PhD

    Medical Education Director, Medscape, LLC


    Disclosure: Melinda Tanzola, PhD, has disclosed no relevant financial relationships.

  • Tristin Abair, PhD

    Medical Writer, Medscape, LLC


    Disclosure: Tristin Abair, PhD, has disclosed no relevant financial relationships.

CME Reviewer

  • Hazel Dennison, DNP, RN, FNP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Peer Reviewer
This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Celgene; Jazz; Pfizer
Received grants for clinical research from: Takeda

Accreditation Statements


In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Induction Therapy for the Older/Unfit Patient

Authors: Daniel A. Pollyea, MD, MSFaculty and Disclosures

CME / ABIM MOC Released: 11/23/2019

Valid for credit through: 11/23/2020


AE = adverse event
AML = acute myeloid leukemia
BCL-2 = B cell lymphoma 2
BM = bone marrow
BSC = best supportive care
CMML = chronic myeloid monocytic leukemia
CR = complete remission
CRi = complete remission with incomplete hematologic recovery
ECOG = Eastern Cooperative Oncology Group
GO = gemtuzumab ozogamicin
HMA = hypomethylating agents
IDH1 = isocitrate dehydrogenase 1
LDAC = low dose ara cytarabine
MDS = myelodysplastic syndrome
MRC = myelodysplasia-related changes
MRD = minimal residual disease
NCCN = National Comprehensive Cancer Network
NE = not estimable
NR = not reported
OS = overall survival
RBC = red blood cell
SEER = Surveillance, Epidemiology, and End Results
TLS = tumor lysis syndrome
WBC = white blood cell

« Return to: Induction Therapy for the Older/Unfit Patient
  • Print